Investment case
Incyte Corporation
INCY · 3 developments mapped · last assessed 2026-09-06
Market Ontology has mapped 3 macro, policy, and market developments to Incyte Corporation since 2026-09-01. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for INCY yet, so no modelled value is shown. The INCY valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run INCY on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics
Increased market opportunity for Opzelura (ruxolitinib cream), a topical JAK inhibitor for atopic dermatitis. While topical, it benefits from the overall market expansion and increased awareness of JAK inhibitors.
· Moves revenue growth rate, market share assumptions
- Open question
Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics Demand
Increased demand for Opzelura (ruxolitinib cream), a topical JAK inhibitor for atopic dermatitis, contributing to dermatology segment revenue.
· Moves revenue growth rate, product pipeline success
What changed, by assumption
- 2026-09-06Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics
- 2026-09-06Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics Demand
- 2026-09-01Disc Medicine to Present Phase 2 RESTORE-PV and RALLY-MF Trial Data at SOHO
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-06-22 | Margin | Bullish | Settlement with CMS regarding Medicaid rebate rules for Opzelura results in a $246M one-time non-cash benefit and improved gross-to-net margins going forward. | 1.00 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-06 | Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics Demand | Bullish | 1-5y | 0.40 |
| 2026-09-06 | Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics | Bullish | 3-12m | 0.60 |
| 2026-09-01 | Disc Medicine to Present Phase 2 RESTORE-PV and RALLY-MF Trial Data at SOHO | watch | 1-3m | 0.20 |